Stay updated on CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Sign up to get notified when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.

Latest updates to the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedRevision: v3.5.4 was added and Revision: v3.5.3 was deleted, reflecting an updated version tag for the record rather than substantive content changes.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe page’s footer revision label was updated from **v3.5.0** to **v3.5.3**.SummaryDifference0.0%

- Check69 days agoChange DetectedAdded Hepatocellular carcinoma to the list of conditions and updated the study version from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check83 days agoChange DetectedThe page revision tag was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check105 days agoChange DetectedAdded 'Gastric cancer' under Conditions and introduced a new Resources link to the Genetic and Rare Diseases Information Center. Removed the older Revision: v3.4.1 entry.SummaryDifference0.2%

- Check112 days agoChange DetectedThe revision label updated from v3.4.0 to v3.4.1. This appears to be a version update with no impact on the study details or page content.SummaryDifference0.0%

Stay in the know with updates to CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Enter your email address, and we'll notify you when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.